0.676
price down icon3.57%   -0.025
after-market After Hours: .68 0.004 +0.59%
loading
Nektar Therapeutics stock is traded at $0.676, with a volume of 3.36M. It is down -3.57% in the last 24 hours and down -43.19% over the past month. Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).
See More
Previous Close:
$0.701
Open:
$0.71
24h Volume:
3.36M
Relative Volume:
1.83
Market Cap:
$123.99M
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-0.463
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
-18.29%
1M Performance:
-43.19%
6M Performance:
-42.71%
1Y Performance:
+0.90%
1-Day Range:
Value
$0.6618
$0.72
1-Week Range:
Value
$0.6618
$0.8565
52-Week Range:
Value
$0.6303
$1.928

Nektar Therapeutics Stock (NKTR) Company Profile

Name
Name
Nektar Therapeutics
Name
Phone
(415) 482-5300
Name
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
Employee
137
Name
Twitter
@nektarnews
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
NKTR's Discussions on Twitter

Compare NKTR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NKTR
Nektar Therapeutics
0.676 123.99M 90.12M -276.06M -193.47M -1.46
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.32 122.13B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
710.00 78.30B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
646.64 39.73B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
276.19 35.50B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.61 28.47B 3.30B -501.07M 1.03B -2.1146

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-08-25 Initiated B. Riley Securities Buy
Dec-10-24 Initiated H.C. Wainwright Buy
Nov-04-24 Initiated Piper Sandler Overweight
Sep-30-24 Resumed BTIG Research Buy
Jun-28-24 Initiated Rodman & Renshaw Buy
Nov-20-23 Resumed JP Morgan Underweight
Nov-09-23 Upgrade TD Cowen Market Perform → Outperform
May-10-23 Upgrade Jefferies Underperform → Hold
Feb-24-23 Downgrade Jefferies Hold → Underperform
Aug-08-22 Downgrade JP Morgan Neutral → Underweight
May-31-22 Resumed Jefferies Hold
Apr-18-22 Downgrade Goldman Neutral → Sell
Mar-15-22 Downgrade Cowen Outperform → Market Perform
Mar-15-22 Downgrade Mizuho Buy → Neutral
Mar-14-22 Downgrade BTIG Research Buy → Neutral
Mar-14-22 Downgrade BofA Securities Neutral → Underperform
Mar-14-22 Downgrade Stifel Buy → Hold
Mar-14-22 Downgrade William Blair Outperform → Mkt Perform
Mar-09-22 Upgrade Oppenheimer Perform → Outperform
Nov-08-21 Upgrade The Benchmark Company Hold → Buy
Sep-10-21 Initiated BofA Securities Neutral
Jun-28-21 Upgrade Stifel Hold → Buy
May-18-21 Resumed Goldman Neutral
Feb-22-21 Downgrade The Benchmark Company Buy → Hold
Jan-06-21 Initiated Stifel Hold
Sep-14-20 Initiated JP Morgan Neutral
Jun-10-20 Downgrade CFRA Hold → Sell
May-12-20 Reiterated H.C. Wainwright Neutral
Apr-22-20 Initiated The Benchmark Company Buy
Mar-30-20 Upgrade Goldman Sell → Neutral
Mar-04-20 Initiated Barclays Overweight
Feb-03-20 Upgrade Mizuho Neutral → Buy
Oct-24-19 Initiated Oppenheimer Perform
Oct-08-19 Downgrade Goldman Buy → Sell
Aug-09-19 Downgrade JP Morgan Overweight → Neutral
Aug-09-19 Downgrade Jefferies Buy → Hold
Aug-09-19 Downgrade Mizuho Buy → Neutral
Mar-15-19 Initiated SVB Leerink Mkt Perform
Dec-13-18 Initiated Goldman Buy
Jun-11-18 Downgrade H.C. Wainwright Buy → Neutral
Jun-04-18 Reiterated H.C. Wainwright Buy
Apr-20-18 Initiated Seaport Global Securities Buy
Apr-13-18 Resumed Piper Jaffray Overweight
Apr-06-18 Reiterated Mizuho Buy
Apr-02-18 Resumed H.C. Wainwright Buy
View All

Nektar Therapeutics Stock (NKTR) Latest News

pulisher
04:37 AM

Nektar Therapeutics (NKTR) Stock Drops Amid Biotech Sector Volat - GuruFocus.com

04:37 AM
pulisher
08:30 AM

Chutes & Ladders—J&J vet jumps to Affinia - Fierce Biotech

08:30 AM
pulisher
Feb 06, 2025

Nektar Therapeutics Sees Unusually High Options Volume (NASDAQ:NKTR) - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Nektar Therapeutics announces senior leadership change - MSN

Feb 06, 2025
pulisher
Feb 04, 2025

Nektar Names Kotzin Interim Chief Medical Officer - MarketWatch

Feb 04, 2025
pulisher
Feb 04, 2025

Metastatic Melanoma Pipeline 2024: MOA and ROA Insights, - openPR

Feb 04, 2025
pulisher
Feb 03, 2025

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance

Feb 03, 2025
pulisher
Jan 26, 2025

Nektar Therapeutics (NASDAQ:NKTR) Shares Purchased by HB Wealth Management LLC - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

B. Riley Securities Initiates Coverage of Nektar Therapeutics (NKTR) with Buy Recommendation - MSN

Jan 25, 2025
pulisher
Jan 25, 2025

JPMorgan Chase & Co. Buys 606,057 Shares of Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat

Jan 25, 2025
pulisher
Jan 25, 2025

JPMorgan Chase & Co. Grows Position in Nektar Therapeutics (NASDAQ:NKTR) - Defense World

Jan 25, 2025
pulisher
Jan 22, 2025

Nurix Therapeutics Taps Former Ibrutinib Commercial Chief to Lead NX-5948 Launch Strategy - StockTitan

Jan 22, 2025
pulisher
Jan 18, 2025

Barclays PLC Purchases 175,596 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

Phase 2b study of rezpegaldesleukin for atopic dermatitis reaches target enrollment - Healio

Jan 17, 2025
pulisher
Jan 17, 2025

Analysts Set Nektar Therapeutics (NASDAQ:NKTR) Price Target at $4.08 - Defense World

Jan 17, 2025
pulisher
Jan 16, 2025

B-Cell Lymphoma Clinical and Non-Clinical Studies, Key - openPR

Jan 16, 2025
pulisher
Jan 15, 2025

Nektar Therapeutics (NASDAQ:NKTR) Stake Lifted by Jane Street Group LLC - Defense World

Jan 15, 2025
pulisher
Jan 13, 2025

LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases - Dermatology Times

Jan 13, 2025
pulisher
Jan 13, 2025

Nektar Therapeutics (NASDAQ:NKTR) Receives "Buy" Rating from HC Wainwright - MarketBeat

Jan 13, 2025
pulisher
Jan 11, 2025

Analysts Issue Forecasts for NKTR FY2024 Earnings - Defense World

Jan 11, 2025
pulisher
Jan 10, 2025

Nektar hits enrollment target for atopic dermatitis study By Investing.com - Investing.com Australia

Jan 10, 2025
pulisher
Jan 10, 2025

Nektar Therapeutics Completes Enrollment for Phase 2b REZOLVE-AD Trial of Rezpegaldesleukin - Dermatology Times

Jan 10, 2025
pulisher
Jan 10, 2025

Nektar hits enrollment target for atopic dermatitis study - Investing.com India

Jan 10, 2025
pulisher
Jan 10, 2025

Nektar Therapeutics (NKTR) competes target enrollment in its REZOLVE-AD Phase 2b study - StreetInsider.com

Jan 10, 2025
pulisher
Jan 10, 2025

Nektar's Key Atopic Dermatitis Drug Trial Hits Full Enrollment Ahead of Schedule - StockTitan

Jan 10, 2025
pulisher
Jan 09, 2025

Nektar Therapeutics to sell Alabama facility to Ampersand - MSN

Jan 09, 2025
pulisher
Jan 09, 2025

B. Riley Upgrades Nektar Therapeutics (NASDAQ:NKTR) to Strong-Buy - MarketBeat

Jan 09, 2025
pulisher
Jan 08, 2025

Nektar stock positioned for growth as B. Riley forecasts REZPEG as key AD market disruptor By Investing.com - Investing.com South Africa

Jan 08, 2025
pulisher
Jan 08, 2025

Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at B. Riley - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Jan 08, 2025
pulisher
Jan 08, 2025

Nektar stock positioned for growth as B. Riley forecasts REZPEG as key AD market disruptor - Investing.com India

Jan 08, 2025
pulisher
Jan 07, 2025

B.Riley Starts Nektar Therapeutics (NKTR) at Buy - StreetInsider.com

Jan 07, 2025
pulisher
Jan 07, 2025

Why Nektar Therapeutics (NKTR) Is Among the Best Penny Stocks to Invest In According to Media? - Yahoo Finance

Jan 07, 2025
pulisher
Jan 06, 2025

12 Best Penny Stocks to Invest in According to the Media - Insider Monkey

Jan 06, 2025
pulisher
Jan 05, 2025

Numerous Nektar Therapeutics Insiders Sold Stock: Not A Positive Omen - Simply Wall St

Jan 05, 2025
pulisher
Jan 04, 2025

Institutional investors have a lot riding on Nektar Therapeutics (NASDAQ:NKTR) with 68% ownership - Yahoo Finance

Jan 04, 2025
pulisher
Dec 28, 2024

Nektar Therapeutics chief legal officer sells shares worth $44,800 By Investing.com - Investing.com Nigeria

Dec 28, 2024
pulisher
Dec 26, 2024

Nektar Therapeutics (NASDAQ:NKTR) Insider Mark Andrew Wilson Sells 33,402 Shares - MarketBeat

Dec 26, 2024
pulisher
Dec 26, 2024

Nektar Therapeutics chief legal officer sells shares worth $44,800 - Investing.com

Dec 26, 2024
pulisher
Dec 21, 2024

Why Nektar Therapeutics May Be About to Take Off - AOL

Dec 21, 2024
pulisher
Dec 21, 2024

Nektar Therapeutics chief R&D officer sells $48,048 in stock By Investing.com - Investing.com Australia

Dec 21, 2024
pulisher
Dec 20, 2024

Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $48,048.10 in Stock - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Nektar Therapeutics chief R&D officer sells $48,048 in stock - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 20, 2024
pulisher
Dec 19, 2024

Howard W. Robin Sells 46,995 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Nektar Therapeutics CEO Robin Howard sells $131,649 in stock By Investing.com - Investing.com Australia

Dec 19, 2024
pulisher
Dec 19, 2024

Nektar Therapeutics CEO Robin Howard sells $131,649 in stock - Investing.com India

Dec 19, 2024

Nektar Therapeutics Stock (NKTR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Nektar Therapeutics Stock (NKTR) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Wilson Mark Andrew
Chief Legal Officer
Dec 24 '24
Sale
0.89
16,560
14,738
335,332
$74.13
price down icon 1.09%
$20.11
price down icon 2.71%
$347.71
price down icon 1.71%
$4.69
price down icon 6.94%
biotechnology ONC
$223.50
price down icon 2.35%
$117.61
price down icon 1.94%
Cap:     |  Volume (24h):